Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Is Drug Researcher Too Cozy With Manufacturers?
Responding to reports of possible conflicts of interest between a drug researcher at the National Cancer Institute and pharmaceutical companies, members of the House Energy and Commerce Committee in August reportedly sent a letter to the National Institutes of Health (NIH) asking for information about researchers' involvement with drug companies. (Willman, The Los Angeles Times, 8/10). There have been allegations that Thomas Walsh, the head of pediatric medical research at the National Cancer Institute, accepted consulting fees and/or research donations from drug manufacturers Merck and Fujisawa. He has also testified before government agencies on behalf of the two companies, something not generally allowed under federal law. The Congressional Committee has asked for several years' worth of Dr. Walsh's financial disclosure statements as well as documents setting out FDA policy on employees testifying on behalf of drug companies before the FDA and its advisory committees.
Human Tissue Processor Shut Down
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
Defining commercial real estate asset class is essentially a property explaining how it identifies — not necessarily what its original intention was or what others think it ought to be. This article discusses, from a general issue-spot and contextual analysis perspective, how lawyers ought to think about specialized leasing formats and the regulatory backdrops that may inform what the documentation needs to contain for compliance purposes.
As courts and discovery experts debate whether hyperlinked content should be treated the same as traditional attachments, legal practitioners are grappling with the technical and legal complexities of collecting, analyzing and reviewing these documents in real-world cases.
How to Convey Your Merits In a Way That Earns Trust, Clients and Distinctions Just as no two individuals have the exact same face, no two lawyers practice in their respective fields or serve clients in the exact same way. Think of this as a "Unique Value Proposition." Internal consideration about what you uniquely bring to your clients, colleagues, firm and industry can provide untold benefits for your law practice.
The ever-evolving digital marketing landscape, coupled with the industry-wide adoption of programmatic advertising, poses a significant threat to the effectiveness and integrity of digital advertising campaigns. This article explores various risks to digital advertising from pixel stuffing and ad stacking to domain spoofing and bots. It will also explore what should be done to ensure ad fraud protection and improve effectiveness.
This article offers practical insights and best practices to navigate the path from roadmap to rainmaking, ensuring your business development efforts are not just sporadic bursts of activity, but an integrated part of your daily success.